AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions

BACKGROUND: Fibroblast growth factor receptor 2 (FGFR2) fusions occur in 13–17% of intrahepatic cholangiocarcinomas (IHC). A multicenter, open-label, phase II study (NCT02150967) evaluated the antitumor activity of infigratinib, an ATP-competitive FGFR1–3-selective oral tyrosine kinase inhibitor, in...

詳細記述

保存先:
書誌詳細
出版年:Hepatobiliary Surg Nutr
主要な著者: Javle, Milind, Kelley, R. Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Borad, Mitesh, Yong, Wei Peng, Borbath, Ivan, El-Khoueiry, Anthony, Philip, Philip, Moran, Susan, Ye, Yining, Ising, Mary, Lewis, Nancy, Bekaii-Saab, Tanios
フォーマット: Artigo
言語:Inglês
出版事項: AME Publishing Company 2019
主題:
Poster Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421211/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn.2019.AB051
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料